Next-Level Neuroscience Innovations: Digital Migraine Therapy, EU Alzheimer’s Approval, AI in MS, Parkinson’s Breakthroughs & More!
🧠 In this week’s Neuroscience Updates, we explore major breakthroughs driving innovation in neurology and neurodegenerative disease treatment:
Key updates include:
📱 FDA approves CT-132, the first mobile-based digital therapy for episodic migraine
🍁 Canada approves ELYXYB, a fast-acting celecoxib oral solution for acute migraine
🤖 Biostate and ACP partner to build RNA-based AI tools to personalize MS treatment
🧪 Octave’s MSDA biomarker test influences clinical decisions in nearly 60% of MS cases
💊 NICE recommends Cladribine as a high-efficacy DMT option for patients with MS
🧠 EU approves Leqembi as the first Alzheimer’s drug to slow disease progression
🚀 AMT-130 gene therapy for Huntington’s receives FDA Breakthrough Therapy status
🧫 Japan’s iPS cell trial shows symptom improvement in 4 of 6 Parkinson’s patients
🔬 FDA clears XellSmart’s iPSC-based therapies for Parkinson’s and ALS; trials begin
🌱 BlueRock’s cell therapy for Parkinson’s shows neuron engraftment, no serious AEs at 18 months
👶 FDA expands VALTOCO seizure spray use to children aged 2–5, improving pediatric care
🌍 New global guidelines recommend pregabalin, duloxetine, and amitriptyline for neuropathic pain
🤝 Lilly and Sangamo sign $1.4B CNS gene therapy deal centered on STAC-BBB capsid tech
🧬 NeuroScientific acquires Isopogen to boost its stem cell pipeline targeting neuroin
📢 Stay Ahead in Neuroscience Research!
✅ Like, share, and subscribe for weekly updates on Neuroscience
#Neuroscience #Migraine #MSResearch #Alzheimers #Parkinsons #Huntingtons #GeneTherapy #DigitalTherapeutics #NeurologyNews #BiotechInnovation #LucidQuest #HealthcareStrategy #NeuroTech